title: Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy.
authors: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, , Tokyo, Japan.
authors: Naoshi
authors: N
authors: Nishina
authors: Jun
authors: J
authors: Kikuchi
authors: Misato
authors: M
authors: Hashizume
authors: Keiko
authors: K
authors: Yoshimoto
authors: Hideto
authors: H
authors: Kameda
authors: Tsutomu
authors: T
authors: Takeuchi
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008163:Luminescent Measurements; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D019947:Receptors, Interleukin-6 / Q000097:blood*; D012074:Remission Induction
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C508600:IL6 protein, human; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; C502936:tocilizumab
keywords: Cytokines; DMARDs (biologic); Disease Activity; Rheumatoid Arthritis; Treatment